Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Correction

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Thomas Dörner1*, Joerg Kaufmann1, William A Wegener2, Nick Teoh2, David M Goldenberg23 and Gerd R Burmester1

Author Affiliations

1 Department of Medicine/Rheumatology and Clinical Immunology, Charite Hospital, Berlin, Germany

2 Immunomedics, Inc., Morris Plains, NJ, USA

3 Center for Molecular Medicine and Immunology, Belleville, NJ, USA

For all author emails, please log on.

Arthritis Research & Therapy 2008, 10:406  doi:10.1186/ar2499


See related research by Dörner et al., http://arthritis-research.com/content/8/3/R74


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/10/5/406


Published:9 September 2008

© 2008 BioMed Central Ltd

Correction

Following publication of our article [1] we noticed an error in the stated dose of methotrexate within the section 'Results', in the paragraph 'Demographics and patient characteristics at study entry'.

In this paragraph, it is stated that two patients were receiving 20 mg/day methotrexate. This should read 20 mg/week methotrexate.

The paragraph should therefore read as follows:

A total of 14 Caucasian patients (13 females and 1 male; 23 to 53 years old, median age 40 years) were enrolled. At study entry, the patients had been initially diagnosed with SLE 1 to 19 years (median 10 years) earlier and were receiving corticosteroids (n = 13, 1 to 12 mg/day prednisolone) plus immunosuppressives (n = 11, including 50 to 200 mg/day azathioprine, n = 9; 20 mg/week methotrexate, n = 2; 2 g/day mycophenalate mofetil, n = 1), and antimalarials (n = 6, 200 to 600 mg/day hydroxychloroquine). All patients had positive ANA at study entry (titers of 80:1 to 5,120:1), and 5 patients (36%) had positive anti-dsDNA antibody levels (> 10 U/ml). Ten patients (71%) had ESR values that were elevated (> 15 mm/h) and 4 patients (29%) had raised CRP levels (> 0.5 mg/dl), while only 3 patients (21%) had C3 levels that were borderline low or decreased (< 90 mg/dl), and no patient had positive direct Coombs' or serum haptoglobulin levels elevated above borderline.

References

  1. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

    Arthritis Research & Therapy 2006, 8:R74. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL